Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
Maya H BuchDeepak L BhattChristina Charles-SchoemanJon T GilesTed MikulsGary G KochSteven YtterbergEdward NagyHyejin JoKenneth KwokCarol A ConnellKarim Richard MasriArne YndestadPublished in: RMD open (2024)
NCT02092467.